Articles Tagged with ''Alzheimer’s disease''

No surprises in briefing docs as Leqembi gets its day before FDA adcom

June 7, 2023
By Jennifer Boggs
Six months after getting accelerated approval from the U.S. FDA without any input from an advisory committee, Eisai Co. Inc. and Biogen Inc.’s Alzheimer’s disease (AD) therapy, Leqembi (lecanemab) will make an appearance June 9 before the Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC), set to discuss the supplemental BLA seeking to convert use of the amyloid beta-targeting antibody to traditional approval.
Read More
Microglia and amyloid plaques in Alzheimer model
Neurology/Psychiatric

Myelin damage distracts microglia from amyloid plaques

June 7, 2023
By Anette Breindl
“One of the many reasons we don’t have effective therapies for AD at the moment ... is that we don’t understand the beginnings of the disease,” Constanze Depp told BioWorld. Understanding those beginnings is likely to be a necessary prerequisite for truly turning the tide on Alzheimer’s disease (AD). “The brain is so bad at repairing itself, and once a neuron is lost, it will most likely not regenerate,” she elaborated. Now, Depp and her colleagues have reported on a contributor to those beginnings.
Read More
Neurology/Psychiatric

Celros Biotech divulges new NOX2 and NOX4 inhibitors

May 30, 2023
Celros Biotech Co. Ltd. has synthesized cytochrome b-245 heavy chain (CYBB; NOX2) and NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, Alzheimer’s disease, cirrhosis, diabetes, cancer, glomerulonephritis, psoriasis and rheumatoid arthritis, among others.
Read More
PET imaging of RELN-COLBOS (H3447R) carrier brain showing limited aggregation of tau
Neurology/Psychiatric

Reelin’ in druggable protective pathways with second Alzheimer’s ‘escapee’

May 15, 2023
By Anette Breindl
Investigators have identified a second individual who remained cognitively normal into his late 60s despite having the PSEN1 E280A mutation, which causes a familial version of early-onset Alzheimer’s disease (AD). The likely source of protection, a mutation in a gene called Reelin, is distinct from the protective mechanism identified in the first case of an individual who was protected from the effects of PSEN1 E280A. That case was reported in 2019.
Read More
Neurology/Psychiatric

Study gives insight into Leqembi MoA

May 10, 2023
By Coia Dulsat
The aqueous supernatants resulting from ultracentrifugation of brain samples from patients with Alzheimer’s disease (AD) contain aggregates so far described as soluble oligomers of amyloid-β protein (Aβ), which are responsible for the neurotoxicity underlying AD and thus considered targets to watch in this devastating condition. Now, a group of scientists from Harvard Medical School have determined that these aggregates are in fact insoluble diffusible fibrils with the same atomic structure as plaque fibrils.
Read More
Amyloid plaques forming between neurons

What CRL? After accelerated diss, Lilly to seek full approval on solid phase III Alzheimer’s readout

May 3, 2023
By Jennifer Boggs
In January, a Wall Street analyst predicted the U.S. FDA’s rejection of Eli Lilly and Co.’s application seeking accelerated approval of amyloid beta-targeting Alzheimer’s candidate, donanemab, would be a “mere footnote” in the drug’s development, a forecast confirmed in the wake of positive top-line phase III data showing donanemab significantly slowed cognitive and functional decline in people with early symptomatic disease.
Read More